Last reviewed · How we verify
MK1006
At a glance
| Generic name | MK1006 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED) (PHASE1)
- A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED) (PHASE1)
- A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED) (PHASE1)
- MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK1006 CI brief — competitive landscape report
- MK1006 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI